(Q51470916)

English

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

scientific article published on 23 May 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. (English)

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

type 2 diabetes

1 reference

based on heuristic

inferred from title

Ralph A. DeFronzo

6

object named as

R A DeFronzo

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

author name string

M Bajaj

1

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

S Suraamornkul

2

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

L J Hardies

3

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

L Glass

4

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

N Musi

5

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

publication date

23 May 2007

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

50

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

8

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

1723-1731

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

https://scigraph.springernature.com/pub.10.1007/s00125-007-0698-9

0 references

PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly

1 reference

https://api.crossref.org/works/10.1007%2FS00125-007-0698-9

21 January 2018

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-007-0698-9

21 January 2018

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1007%2FS00125-007-0698-9

21 January 2018

Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects

1 reference

https://api.crossref.org/works/10.1007%2FS00125-007-0698-9

21 January 2018

Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates

1 reference

https://api.crossref.org/works/10.1007%2FS00125-007-0698-9

21 January 2018

Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endogenous glucose production is inhibited by the adipose-derived protein Acrp30

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of hormone-stimulated lipolysis by clofibrate. A possible mechanism for its hypolipidemic action

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influences of glucose loading and of injected insulin on hepatic glucose output

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic roles of peroxisome proliferator-activated receptor agonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucose clamp technique: a method for quantifying insulin secretion and resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of hypertriglyceridaemia in diabetic patients with fasting hyperglycaemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17520238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-007-0698-9

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17520238

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51470916&oldid=1794167959"